Outlook

2019

Revenue growth
- constant currency1 3 - 6%
- reported currency2 Around 0.7 pp higher
Operating profit margin
- constant currency1 8 - 9%3
- reported currency2 Around 0.4 pp lower
Capital expenditures4
- re-investments and new client investments 5 - 7% of revenue

1Constant currencies measured using average exchange rates for 2018

2Based on exchange rates as of May 7, 2019

3Excluding restructuring costs associated with the likely loss of the PANDORA agreement as communicated on July 3 2019

4Investments and re-investments are in 2019 expected to be between 5-7 percent of total revenue. Please note that the acquistion of HGP is not included as part of NNIT's investment/revenue guidance

Long term
- Organic Revenue Growth excl. Novo Nordisk Group 6 - 8%
- Operating profit margin At least 10%

Disclaimer

This website contains forward-looking statements. Forward-looking statements are statements that are not historical facts and that generally reflect the current views or expectations of management of NNIT with respect to future events or conditions, including future operational or financial performance. These statements may be identified by words such as "anticipate", "estimate", "expect", "intend", "seek", "will" or words of similar meaning. Such statements are based on expectations and various assumptions, and although NNIT believes that the expectations and assumptions were reasonably made, these are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors, which are difficult or impossible to predict and are beyond NNIT's control and which could cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements.

Factors that may affect future results include, but are not limited to, global and local economic conditions, NNIT's ability to realise backlog as net turnover, manage international operations, maintain and improve operating margins, manage an increasingly complex business as its customer base is increased and correctly assess costs, pricing and other contractual terms, changes in the demand for IT services, in particular, in the Danish and international life sciences markets, changes in any applicable laws and regulations or any interpretations thereof and competition from Danish and international companies in the markets in which NNIT operates.

Investor relations contact

Klaus Hosbond Skovrup
Head of Investor Relations

Email
+45 3079 5355

Email alerts

To subscribe to receive updates by email.

Subscribe

Follow NNIT